For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Rosuvastatin calcium - Lipid modification
PAD Profile : Rosuvastatin calcium - Lipid modification
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Atorvastatin
- Simvastatin
- Ezetimibe
- Pravastatin sodium
- Fluvastatin sodium
- Evolocumab
- Alirocumab
- Fenofibrate
- Bezafibrate
- Ciprofibrate
- Gemfibrozil
- Colesevelam hydrochloride
- Colestyramine
- Bempedoic acid
- Inclisiran
- Icosapent
Other Indications
No indications returned.
Additional Documents
Committee Recommendations
Rosuvastatin is not a cost-effective treatment option for most patients and should be reserved for a small number of individual patients where high-intensity statin therapy is appropriate but the alternatives are not tolerated or are contraindicated.
Rosuvastatin should ONLY be considered as GREEN on the traffic light system for these individual patients.
NICE published CG 181 in July 2014 to update and replace NICE CG 67 and NICE TA 94 (statins for the prevention of cardiovascular events). This new NICE guidance does not mention rosuvastatin so the PCN sought clarification from NICE - see update following clarification from NICE below.
If statin therapy is considered appropriate the guidelines recommend using atorvastatin 20mg for primary prevention and atorvastatin 80mg for secondary prevention.